Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a hold rating to a buy rating in a report released on Friday morning.

Separately, Hsbc Global Res raised shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Monday, April 28th.

Bayer Aktiengesellschaft Trading Up 0.9%

OTCMKTS BAYRY opened at $7.59 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19. The stock’s 50-day simple moving average is $6.45 and its two-hundred day simple moving average is $5.87. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $8.58. The company has a market capitalization of $29.83 billion, a price-to-earnings ratio of -29.19 and a beta of 0.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The company had revenue of $15.27 billion for the quarter, compared to analysts’ expectations of $13.39 billion. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. Research analysts forecast that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Increases Dividend

The business also recently declared a dividend, which was paid on Monday, May 12th. Shareholders of record on Wednesday, April 30th were paid a $0.0224 dividend. This is a boost from Bayer Aktiengesellschaft’s previous dividend of $0.02. This represents a yield of 0.38%. The ex-dividend date was Tuesday, April 29th. Bayer Aktiengesellschaft’s payout ratio is -2.17%.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.